If you’re talking about patient management, there is no question about the value of CGM and time in range, because HbA1c is really not worth anything for management. HbA1c is not actionable.

Time in range emerged as a prominent theme among diabetes experts as early as 2016, ... Time in range — not HbA1c — should guide most diabetes treatment decisions. ByRegina Schaffer.

Time in range, made possible by ... boil the mixture for at least five minutes, and then compare the color to a chart. ... its corresponding average HbA1c, and the time in range. ...

Maintaining Time in Range can significantly reduce the risk of diabetes-related complications; Time in Range empowers people with immediate feedback on their choices and develops a more engaged, ...

For older adults with diabetes, having a more stable hemoglobin A1c (HbA1c) level over time may be associated with a lower risk of Alzheimer disease and dementia, a new study finds.

The iLet® Bionic Pancreas Significantly Reduced HbA1c and Improved Time in Range vs Standard of Care for a Diverse Range of People with Type 1 Diabetes Beta Bionics, Inc. Sat, Apr 30, 2022, 1:00 ...

Lower HbA1c time in range may identify patients at increased risk of Alzheimer disease and related dementias. Corresponding Author: To contact the corresponding author, Paul R. Conlin, MD, email ...

Meeting Coverage > ADA Expert Panel Defines CGM Time-in-Range Targets — Seventy percent of readings should stay between 70-180 mg/dL, according to recommendations ...

Increased time in range: People who used the iLet Bionic Pancreas had an average of 2.6 hours more time in range per day over the 13 weeks than those using standard of care. Beta Bionics is committed ...